Immediate Impact

2 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
2024 Standout
2 intermediate papers

Works of Emi Kamiyama being referenced

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
2021
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
2017

Author Peers

Author Last Decade Papers Cites
Emi Kamiyama 289 45 50 109 84 22 467
Daria Stypinski 164 39 97 80 78 29 548
Maria M. Posada 260 46 14 116 113 21 493
B Booth 170 35 46 79 86 17 520
Kenji Tabata 210 26 16 67 112 29 551
Eric Y. Zhang 185 6 43 76 125 11 412
Lucy Sasongko 333 9 43 285 62 21 524
Ryosei Kawai 108 16 29 51 99 16 476
Sumihisa Kimura 221 14 53 35 114 13 525
Sarinj Fattah 167 23 8 75 148 16 470
Manford C. Castle 185 53 14 44 142 22 465

All Works

Loading papers...

Rankless by CCL
2026